BLUE · Bluebird Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.71M | - | $12.28M | $16.10M | $18.57M | - | $12.39M | $6.89M | $2.38M | - |
| Cost of Revenue | $12.24M | - | $11.78M | $28.95M | $25.86M | - | $10.96M | $1.75M | $3.38M | - |
| Gross Profit | $26.48M | - | ($1.17M) | ($12.85M) | ($7.29M) | - | $71.0K | ($2.67M) | ($6.37M) | - |
| R&D | $17.72M | - | $23.17M | $25.16M | $25.07M | - | $45.46M | $42.27M | $46.14M | - |
| SG&A | $30.26M | - | $39.77M | $50.38M | $46.33M | - | $40.70M | $40.35M | $37.35M | - |
| Total Operating Expenses | $51.08M | - | $65.75M | $75.55M | $71.40M | - | $86.17M | $82.62M | $83.50M | - |
| D&A | $15.54M | - | - | - | $15.47M | - | - | - | $1.08M | - |
| Operating Income | ($24.61M) | - | ($66.92M) | ($88.39M) | ($78.69M) | - | ($84.73M) | ($85.30M) | $8.44M | - |
| Interest Expense | $4.86M | - | $4.31M | $3.75M | $4.86M | - | - | - | - | - |
| Income Tax | $100.0K | - | ($58.0K) | $21.0K | $0 | - | $0 | ($80.0K) | $0 | - |
| Net Income | ($29.07M) | - | ($60.81M) | ($81.39M) | ($69.80M) | - | ($71.73M) | ($72.91M) | $21.24M | - |
| EPS - Basic | ($2.98) | - | ($0.31) | ($0.42) | ($0.36) | - | ($0.66) | ($0.67) | $0.21 | - |
| EPS - Diluted | ($2.98) | - | ($0.31) | ($0.42) | ($0.36) | - | ($0.66) | ($0.67) | $0.21 | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.74M | $62.30M | $70.65M | $144.07M | $212.05M | $221.75M | $165.35M | $172.87M | $239.04M | $113.01M |
| Accounts Receivable | - | - | - | - | - | - | $0 | - | - | - |
| Inventory | $83.28M | $65.02M | $53.94M | $33.33M | $30.30M | $22.92M | $20.97M | $13.64M | $3.81M | - |
| Accounts Payable | $42.62M | $34.32M | $24.48M | $30.59M | $19.39M | $18.50M | $19.85M | $10.89M | $19.23M | $25.09M |
| Current Assets | $174.52M | $154.67M | $150.81M | $203.52M | $271.60M | $281.69M | $247.08M | $287.98M | $351.07M | $199.49M |
| Total Assets | $295.96M | $460.23M | $465.06M | $545.19M | $631.48M | $619.16M | $613.61M | $663.39M | $692.74M | $554.90M |
| Current Liabilities | $315.08M | $321.46M | $296.03M | $297.93M | $293.57M | $200.11M | $158.96M | $135.02M | $115.93M | $128.24M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $353.82M | $491.77M | $470.84M | $492.21M | $500.44M | $424.62M | $391.07M | $374.37M | $338.00M | $358.56M |
| Stockholders' Equity | ($57.87M) | ($31.53M) | ($5.79M) | $52.98M | $131.05M | $194.54M | $222.54M | $289.02M | $354.74M | $196.34M |
| Retained Earnings | ($4.53B) | ($4.50B) | ($4.47B) | ($4.41B) | ($4.33B) | ($4.26B) | ($4.11B) | ($4.04B) | ($3.97B) | ($3.99B) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($43.44M) | - | - | - | ($74.68M) | - | - | - | ($86.64M) | - |
| Investing Cash Flow | $3.10M | - | - | - | ($655.0K) | - | - | - | $82.14M | - |
| Financing Cash Flow | $26.71M | - | - | - | $64.64M | - | - | - | $130.46M | - |
| CapEx | $859.0K | - | - | - | $1.77M | - | - | - | $232.0K | - |
| Free Cash Flow | ($44.30M) | - | - | - | ($76.45M) | - | - | - | ($86.87M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.4% | - | -9.5% | -79.8% | -39.3% | - | 0.6% | -38.8% | -267.3% | - |
| Operating margin | -63.6% | - | -544.9% | -549.0% | -423.7% | - | -683.7% | -1238.0% | 354.3% | - |
| EBITDA margin | -23.4% | - | - | - | -340.4% | - | - | - | 399.8% | - |
| Net margin | -75.1% | - | -495.1% | -505.5% | -375.8% | - | -578.8% | -1058.2% | 892.1% | - |
| Free cash flow margin | -114.4% | - | - | - | -411.6% | - | - | - | -3648.5% | - |
| FCF / Net income | 1.52 | - | - | - | 1.10 | - | - | - | -4.09 | - |
| R&D / Revenue | 45.8% | - | 188.7% | 156.3% | 135.0% | - | 366.9% | 613.6% | 1938.0% | - |
| SG&A / Revenue | 78.2% | - | 323.8% | 312.9% | 249.4% | - | 328.5% | 585.6% | 1568.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | -9.8% | - | -13.1% | -14.9% | -11.1% | - | -11.7% | -11.0% | 3.1% | - |
| Return on equity | 50.2% | - | 1051.0% | -153.6% | -53.3% | - | -32.2% | -25.2% | 6.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.55 | 0.48 | 0.51 | 0.68 | 0.93 | 1.41 | 1.55 | 2.13 | 3.03 | 1.56 |
| Quick ratio | 0.29 | 0.28 | 0.33 | 0.57 | 0.82 | 1.29 | 1.42 | 2.03 | 3.00 | 1.56 |
| Cash ratio | 0.25 | 0.19 | 0.24 | 0.48 | 0.72 | 1.11 | 1.04 | 1.28 | 2.06 | 0.88 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.1x | - | -15.5x | -23.6x | -16.2x | - | - | - | - | - |
| Equity multiplier | -5.11 | -14.59 | -80.38 | 10.29 | 4.82 | 3.18 | 2.76 | 2.30 | 1.95 | 2.83 |
| Liabilities / Assets | 1.20 | 1.07 | 1.01 | 0.90 | 0.79 | 0.69 | 0.64 | 0.56 | 0.49 | 0.65 |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | - | 0.03 | 0.03 | 0.03 | - | 0.02 | 0.01 | 0.00 | - |
| Inventory turnover | 0.15 | - | 0.22 | 0.87 | 0.85 | - | 0.52 | 0.13 | 0.89 | - |
| Days sales outstanding | - | - | - | - | - | - | 0d | - | - | - |
| Days inventory outstanding | 2484d | - | 1671d | 420d | 428d | - | 699d | 2853d | 412d | - |
| Days payable outstanding | 1271d | - | 758d | 386d | 274d | - | 661d | 2279d | 2080d | - |
| Cash conversion cycle | - | - | - | - | - | - | 37d | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 108.4% | - | -0.9% | 133.7% | 680.1% | - | 17353.5% | 353.6% | 22.4% | - |
| Revenue CAGR (3y) | 171.0% | - | -18.5% | 29.2% | 13.2% | - | 11.6% | -67.4% | -52.2% | - |
| Revenue CAGR (5y) | 12.1% | - | 6.6% | 3.9% | 8.3% | - | 1.5% | -2.6% | -31.6% | - |
| Gross profit growth (YoY) | - | - | - | -380.4% | -14.5% | - | 0.0% | -1083.2% | 0.0% | - |
| Operating income growth (YoY) | 68.7% | - | 21.0% | -3.6% | - | - | 0.1% | 20.6% | - | - |
| Net income growth (YoY) | 58.4% | - | 15.2% | -11.6% | - | - | 6.3% | 27.2% | - | - |
| EPS growth (YoY) | -727.8% | - | 53.0% | 37.3% | - | - | 29.8% | 50.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 42.1% | - | - | - | 12.0% | - | - | - | 31.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -81.7% | -63.1% | -0.9% | 40.1% | 60.5% | 34.7% | -47.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$83.80M totalZYNTEGLO$62.27M · 74.3%
LYFGENIA$11.61M · 13.8%
SKYSONA$9.92M · 11.8%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing bluebird bio against the 5 most active filers in the same SIC group.